GE-HEALTHCARE
GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006355/en/
GE HealthCare is innovating in contrast media (Photo: Business Wire)
The macrocyclic, extra-cellular – or general-purpose – manganese-based contrast agent has comparable relaxivity - the ability of a contrast agent to enhance signal intensity during an MRI scan - and is expected to be diagnostically similar to current gadolinium-based contrast agents (GBCAs). Unlike gadolinium, manganese is endogenous, meaning that it is a trace element that is naturally occurring in and efficiently eliminated from the body. Along with its magnetic properties, this makes a manganese-based agent a viable alternative to gadolinium. In addition, a non-gadolinium agent could help limit the potential impact of post-patient excreted gadolinium in the environment.
The clinical trial, based at the clinical research unit at the Oslo University Hospital, Rikshospitalet, Norway, and overseen by Lead Investigator, Hasse K. Zaré, aims to investigate the safety profile and how this injectable manganese contrast agent is eliminated from the body in healthy volunteers. Previous manganese-based MRI agents have been reliant on a ‘free manganese’ release mechanism for their imaging efficacy. This novel investigational agent is tightly bound to the chelate, in a macrocyclic cage-like structure, so it is rapidly eliminated from - rather than actively released into - the body.
Dr Paul Evans, Head of Global R&D at GE HealthCare’s Pharmaceutical Diagnostics unit, said: “For many years we’ve been committed to investing in, and bringing to market, products to help solve some of radiology’s biggest challenges and unmet needs. This manganese-based MRI agent is one of a number of novel agents we have at various stages of development in our innovation pipeline, all of which aim to give practitioners more choice in delivering precision care for their patients.”
GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doha Debates Reflects on a Landmark Year of Global Dialogue and Youth Engagement19.1.2026 17:02:00 CET | Press release
In 2026, Doha Debates addresses the world’s most pressing questions through global dialogue that engages diverse audiences, including youth In 2025, Qatar Foundation’s Doha Debates strengthened its role as a global platform for truth-seeking dialogue, bringing students and leading thinkers together to explore ideas shaping today’s most urgent questions––from freedom and justice to identity and belonging. Its reach continued to grow, surpassing 13.8 million video views and engaging nearly seven million followers across social platforms, including more than one million YouTube subscribers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119796451/en/ In 2026, Doha Debates addresses the world’s most pressing questions through global dialogue that engages diverse audiences, including youth. (Photo: AETOSWire) A major milestone came with season four of The Negotiators, which earned international recognition, winning the Folio A
Evernote Releases v11, Marking a New Chapter in AI-Powered Productivity19.1.2026 17:00:00 CET | Press release
Evernote today announced the release of v11, its first major product update in five years. The new version includes three powerful AI features—AI Assistant, Semantic Search, and AI Meeting Notes—creating smarter ways to capture, retrieve, and manage information in Evernote. With the release of v11, these features are now available to all Evernote customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119103272/en/ Two years of work culminating in a major update V11 is a recognition of Evernote’s evolution under Bending Spoons’ stewardship. Since 2024, Evernote has released more than 250 new features and improvements while also greatly enhancing sync, speed, and reliability. With v11, Evernote ushers in an exciting new phase of development and innovation, bringing customers novel ways to engage with their preferred productivity tool. “Evernote has been part of people’s lives for years, often decades. They’ve always insp
Esmark Expands Global Sports Commitment With Sponsorship of Slovakian Professional Hockey Team19.1.2026 14:00:00 CET | Press release
Sponsorship unites local talent and gives the people of Košice a team of their own Esmark Sports Management and Entertainment, a wholly owned subsidiary of Esmark Inc., announced today it is the team sponsor and co-owner of a newly established professional hockey team in Košice, Slovakia. This partnership underscores Esmark’s commitment to supporting sports development and strengthening community connections through the unifying power of athletics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119104207/en/ Esmark Sports Management and Entertainment, a wholly owned subsidiary of Esmark Inc., is the team sponsor and co-owner of a newly established professional hockey team in Košice, Slovakia. The Hockey Club Esmark Košice team began competing in the 2HL division of professional ice hockey in Slovakia in the 2025-2026 season. The roster features players from Košice who have been competing for clubs across Slovakia. “The cr
WHOOP Becomes Official Health and Fitness Wearable Partner and Team Partner of Scuderia Ferrari HP19.1.2026 13:38:00 CET | Press release
A First in Formula 1: WHOOP to Deliver Health Insights Across the Scuderia Ferrari HP Team WHOOP, the human performance company, today announced a new, global partnership with Scuderia Ferrari HP as the Official Health and Fitness Wearable Partner and Team Partner. Starting in the 2026 season, Scuderia Ferrari HP cars and drivers will host the WHOOP logo, while WHOOP will be provided to members of the team to unlock insights on their health, recovery, and fitness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119602892/en/ This partnership also unlocks a first-of-its-kind integration in which the medical team supporting Scuderia Ferrari HP will work closely with the WHOOP Performance Science team, led by Dr. Kristen Holmes, on enhancing the physical efficiency and recovery for the entire Scuderia Ferrari HP organization. Together, they will work on the foundational elements of health and fitness with a unique human optim
Logistics Reply Announces the Launch of Its Warehouse AI Agent Builder, GaliLEA Dynamic Intelligence19.1.2026 12:32:00 CET | Press release
Logistics Reply, the Reply group company specialising in innovative solutions for supply chain execution and warehouse management, announced today the release of GaliLEA Dynamic Intelligence, the new AI Agent Builder, part of its agentic AI solution natively embedded within the LEA ReplyTM Platform, the microservices-based platform for warehouse and supply chain execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119708355/en/ LEA Reply enables end-to-end supply chain execution while continuously evolving to address increasing levels of automation and operational complexity. Designed to support warehouse operations through a flexible and scalable architecture, LEA Reply enables end-to-end supply chain execution while continuously evolving to address increasing levels of automation and operational complexity. With the introduction of GaliLEA Dynamic Intelligence, the platform enables users to design, configure, and d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom